Inventor · disambiguated record
Johan Renes
Also filed as: RENES JOHAN
4 granted patents·25 pending applications·16 citations·filing 2001–2025
72Inventor score
Files withAPO T B V14BIOTEMPT BV2CROSSBETA BIOSCIENCES BV2GEBBINK MARTIJN FRANS BEN GERARD2VELDHUIZEN MARK2
Top patents by PatentIndex Score
29 records- 0183US11098115B2Multi-specific binding molecules targeting aberrant cellsAPO T B V·Filed 2012·Granted Aug 24, 2021·7 cites·13 claims
- 0273US2025115662A1Multi-specific binding molecules targeting aberrant cellsAPO T B V·Filed 2024·Application pending·0 cites
- 0370US10946104B2Aberrant cell-restricted immunoglobulins provided with a toxic moietyAPO T B V·Filed 2013·Granted Mar 16, 2021·1 cites·11 claims
- 0466US8301469B1Mortgage insurance systemVELDHUIZEN MARK·Filed 2009·Granted Oct 30, 2012·6 cites·8 claims
- 0565US9821073B2Polypeptide that binds aberrant cells and induces apoptosisVAN DRIEL MARIA JOHANNA J E·Filed 2011·Granted Nov 21, 2017·2 cites·6 claims
- 0664US2021205465A1Aberrant cell-restricted immunoglobulins provided with a toxic moietyAPO T B V·Filed 2021·Application pending·0 cites
- 0762US2021355209A1Multi-specific binding molecules targeting aberrant cellsAPO T B V·Filed 2021·Application pending·0 cites
- 0859US2011052564A1Enhancement of immunogenicity of antigensGEBBINK MARTIJN FRANS BEN GERARD·Filed 2008·Application pending·0 cites
- 0958US2020339669A1Binding molecules targeting pathogensAPO T B V·Filed 2020·Application pending·0 cites
- 1058US2025230403A1Methods and means for attracting immune effector cells to tumor cellsAPO T B V·Filed 2025·Application pending·0 cites
- 1156US2018154013A1Aberrant cell-restricted immunoglobulins provided with a toxic moietyAPO T B V·Filed 2017·Application pending·0 cites
- 1256US2021238543A1Methods and means for attracting immune effector cells to tumor cellsAPO T B V·Filed 2019·Application pending·0 cites
- 1355US2024016882A1Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeabilityBIOTEMPT BV·Filed 2021·Application pending·0 cites
- 1452US2018105587A1Binding molecules targeting pathogensAPO T B V·Filed 2017·Application pending·0 cites
- 1552US2013046564A1Separation insurance systemVELDHUIZEN MARK·Filed 2012·Application pending·0 cites
- 1651US2011287047A1Cross-beta structures as carrier in vaccinesBOUMA BAREND·Filed 2009·Application pending·0 cites
- 1751US2023241155A1Methods and means for modifying hemodynamics in infectionsBIOTEMPT BV·Filed 2021·Application pending·0 cites
- 1851US2018071398A1Polypeptide that binds aberrant cells and induces apoptosisAPO T B V·Filed 2017·Application pending·0 cites
- 1950US2015202318A1Aberrant cell-restricted immunoglobulins provided with a toxic moietyAPO T B V·Filed 2015·Application pending·0 cites
- 2048US2011008376A1Immunogenic compositions capable of activating t-cellsGEBBINK MARTIJN FRANS BEN GERARD·Filed 2008·Application pending·0 cites
- 2148US2012123218A1Methods and means for clinical investigationsRENES JOHAN·Filed 2010·Application pending·0 cites
- 2248US2015175683A1Binding molecules targeting pathogensAPO T B V·Filed 2013·Application pending·0 cites
- 2347US2023046744A1Methods and means for attracting immune effector cells to tumor cellsAPO T B V·Filed 2020·Application pending·0 cites
- 2446US2014336475A1Methods and Means for Clinical InvestigationsJPWaVe·Filed 2014·Application pending·0 cites
- 2546US2009142377A1Immunogenic compositionsCROSSBETA BIOSCIENCES BV·Filed 2008·Application pending·0 cites
- 2644US2009191228A1Immunogenic compositions capable of activating T-cellsCROSSBETA BIOSCIENCES BV·Filed 2008·Application pending·0 cites
- 2743US2005282169A1Signatory sequencesTURNER ALLEN C·Filed 2004·Application pending·0 cites
- 2842US2003074231A1Insurance for cessation of legal personal contractFiled 2001·Application pending·0 cites
- 2936US2002176860A1Fusion proteins for specific treatment of cancer and autoimmune diseasesFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Johan Renes files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →